False positive newborn hearing screening results and autism spectrum disorder

新生儿听力筛查结果假阳性与自闭症谱系障碍

• 批准号: 10296153
• 负责人: Nicole Talge
• 金额: $ 32.82万
• 依托单位: MICHIGAN STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10296153
• 关键词: Age; Age-Months; Attention deficit hyperactivity disorder; Auditory Brainstem Responses; Auditory Perception; Base of the Brain; Behavior; Behavioral Symptoms; Biodiversity; Biological Markers; Biological Process; Birth Certificates; Brain; Brain Stem; CNS processing; Cephalic; Child; Cochlea; Data; Data Set; Databases; Detection; Development; Diagnosis; Diagnostic; Disease; Electrophysiology (science); Enrollment; Epigenetic Process; Epilepsy; Esthesia; Etiology; Exhibits; Failure; Family; Future; Genetic; Hearing; Heterogeneity; Hospitals; Immune; Individual; Infant; Intellectual functioning disability; Intervention; Lead; Link; Magnetic Resonance Imaging; Measurable; Medicaid; Medical; Metabolic; Michigan; Morphology; Neonatal Screening; Neurodevelopmental Disorder; Newborn Infant; Pathway interactions; Perinatal; Premature Birth; Premature Infant; Process; Public Health; Recording of previous events; Records; Research; Risk; Risk Assessment; Risk Factors; Sampling; Screening Result; Siblings; Structure; Subgroup; Symptoms; Target Populations; Time; Treatment Efficacy; Ultrasonography; United States; United States Dept. of Health and Human Services; administrative database; auditory processing; autism onset; autism spectrum disorder; autistic children; base; comorbidity; disorder risk; follow-up; health administration; hearing impairment; hearing screening; improved; indexing; infancy; interest; male; perinatal brain; perinatal health; population based; postnatal; postnatal period; predictive marker; prenatal; prospective; response; risk prediction; screening; screening program; sex; sociodemographics; stem

Abstract Biomarkers have garnered great interest in the study of autism spectrum disorder (ASD) due to their potential to inform etiology as well as diagnostic risk prediction. Despite the diversity of biological processes implicated in ASD (epigenetic, metabolic, immune), final common pathways involve disruptions to prenatal and/or early postnatal brain development. As a result, brain-based biomarkers – particularly those that can be assessed during early infancy -- hold unique potential in advancing our understanding of the disorder. To this end, auditory brainstem responses (ABRs) may be a biomarker worth further consideration. ABRs exhibit strong cross-sectional associations with ASD, can be non-invasively and reliably assessed in young infants, and are a common target of population-based newborn hearing screening programs. However, it remains unclear whether ABR alterations precede the onset of ASD symptoms, are confounded by or interact with known ASD risk factors (e.g., family history, perinatal risk), or generalize to other neurodevelopmental disorders (e.g., attention deficit hyperactivity disorder). The objective of this proposal is to evaluate whether false positive, ABR-based newborn hearing screening results (i.e., failure in the absence of hearing loss) are prospectively associated with ASD. To do this, we will combine and analyze Michigan Department of Health and Human Services (MDHHS) datasets from 2004- 2020: newborn hearing screening records, birth certificates, and Medicaid claims. As part of this effort, we will evaluate whether findings differ according to known ASD risk factors (male sex; preterm delivery; sibling ASD diagnosis) and comorbidities (intellectual disability; epilepsy). We will also examine whether false positive newborn hearing screening findings are associated with attention deficit hyperactivity disorder (ADHD) – a neurodevelopmental disorder that, like ASD, is linked to perinatal etiologies as well as ABR alterations. Findings from this rigorous and well-powered population-based analysis have the potential to launch multiple lines of research that may lead to breakthroughs in our understanding of and surveillance for ASD.

摘要 生物标志物由于其潜在的应用价值，在自闭症谱系障碍（ASD）的研究中引起了极大的兴趣 以告知病因学以及诊断风险预测。尽管生物过程的多样性 在ASD（表观遗传、代谢、免疫）中，最终共同途径涉及产前和/或早期 出生后的大脑发育因此，基于大脑的生物标志物-特别是那些可以评估的生物标志物- 在婴儿早期--在促进我们对这种疾病的理解方面具有独特的潜力。 为此，听觉脑干反应（ABR）可能是值得进一步考虑的生物标志物。ABR 表现出与ASD的强横截面关联，可以在年轻人中进行非侵入性和可靠的评估。 婴儿，并且是基于人群的新生儿听力筛查计划的常见目标。但 目前尚不清楚ABR改变是否先于ASD症状发作，是否与ASD症状混淆或相互作用 具有已知的ASD风险因素（例如，家族史，围产期风险），或推广到其他神经发育 疾病（例如，注意力缺陷多动障碍）。 本建议的目的是评估是否假阳性，ABR为基础的新生儿听力筛查 结果（即，在没有听力损失的情况下失败）与ASD前瞻性相关。为此，我们将 联合收割机并分析密歇根州卫生和人类服务部（MDHHS）2004年的数据集- 2020年：新生儿听力筛查记录，出生证明和医疗补助索赔。作为这项努力的一部分，我们将 根据已知的ASD风险因素（男性;早产;兄弟姐妹ASD）评估结果是否不同 诊断）和合并症（智力残疾;癫痫）。我们还将检查假阳性是否 新生儿听力筛查结果与注意缺陷多动障碍（ADHD）相关- a 神经发育障碍，如ASD，与围产期病因学以及ABR改变有关。 这项基于人群的严格和有力的分析结果有可能启动多项研究。 这些研究可能会导致我们对ASD的理解和监测的突破。